3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Carcinoma in Situ
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Hairy Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Burkitt Lymphoma
1
Anus Neoplasms
1
Interventions
Dexamethasone
124
Lenalidomide
72
daratumumab
71
Bortezomib
58
pomalidomide
47
carfilzomib
42
Cyclophosphamide
39
Calcium Dobesilate
36
Specimen Handling
31
Biopsy
29
Magnetic Resonance Spectroscopy
26
belantamab mafodotin
22
isatuximab
21
fludarabine
20
iberdomide
18
talquetamab
17
Melphalan
15
dexamethasone acetate
14
dexamethasone 21-phosphate
14
auricularum
14
fludarabine phosphate
13
elotuzumab
12
selinexor
10
tocilizumab
9
X-Rays
8
Nivolumab
8
trametinib
7
Whole-Body Irradiation
7
Sirolimus
7
Mycophenolic Acid
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
Diphenhydramine
×
90 days
×
Clear all
NCT04268498
2026-03-24
ADVANCE
University of Miami
Phase 2
Active not recruiting
310 enrolled
NCT05896228
2026-03-11
Iber-KDd
University of Miami
Phase 2
Recruiting
30 enrolled